Irvington, New York -- Therapeutic device company Orthocon has signed an exclusive, worldwide license agreement with Bezwada Biomedical to develop and commercialise Bezwada's technology for bone applications.
Bezwada Biomedical of Hillsborough, New Jersey, has proprietary technology platforms that comprise bioabsorbable and biocompatible polyurethanes and polyamides derived from hydrolyzable isocyanates, Orthocon said in a 31 Aug announcement.
The technology can be used to create absorbable surgical devices for a variety of applications including structural support, fixation, and drug delivery, with the potential to address significant limitations of existing therapeutic modalities.
"This strategic partnership is another important milestone for Orthocon as it significantly enhances the company's technological capabilities and product pipeline," said John Pacifico, ceo of Irvington, New York-based Orthocon.
He added, "Bezwada Biomedical has invented new technology that clearly improves upon existing marketed products, and we are very pleased to be working with Dr Bezwada and his team to develop and commercialise additional devices that address the needs of our surgeon customers."
The companies said they were enthusiastic about the opportunities to overcome "important problems in orthopaedic and other surgical specialities."